Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03633734

Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma

Efficacy Evaluation of Sequential Treatment With Nab-paclitaxel Plus Gemcitabine and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions Chemotherapy Effect Pancreatic Adenocarcinoma Metastatic

Interventions Sequential Treatment

Updated 5 times since 2018 Last updated: Aug 20, 2018 Started: Jul 1, 2018 Primary completion: Aug 31, 2023 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03633734, this PHASE1/PHASE2 trial focuses on Chemotherapy Effect and Pancreatic Adenocarcinoma Metastatic and remains ongoing. Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University, it has been updated 5 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Feb 2025 — Present [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Sep 2018 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jul 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Data source: Second Affiliated Hospital, School of Medicine, Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China